<p>More accurate than a rapid antigen test and almost as quick, India’s CRISPR ‘Feluda’ Covid-19 test that changes colour on detection of the SARS-CoV-2 virus could be a cheaper, faster and simpler alternative to an RT-PCR diagnosis, say scientists.</p>.<p>Named after Satyajit Ray’s famed detective, the Feluda test, which is priced at Rs 500 and can deliver a result in 45 minutes, is able to differentiate SARS-CoV-2 from other coronaviruses even if genetic variations between them are minute.</p>.<p>The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Feluda test, developed by the New Delhi-based CSIR-Institute of Genomics and Integrative Biology (IGIB) and the TATA Group, received regulatory approvals last week from the Drug Controller General of India (DCGI) for commercial launch.</p>.<p>It meets high quality benchmarks with 96 per cent sensitivity and 98 per cent specificity for detecting the novel coronavirus, Debojyoti Chakraborty, a senior scientist at CSIR-IGIB and part of the team that developed the test, told PTI.</p>.<p>Sensitivity is defined as the ability of a test to correctly identify individuals with the disease, while specificity is the ability of the assay to accurately identify those without the disease.</p>.<p><strong><a href="https://www.deccanherald.com/national/coronavirus-news-live-updates-india-world-coronavirus-vaccine-astrazeneca-Covid-19-karnataka-bengaluru-maharashtra-mumbai-tamil-nadu-chennai-delhi-kerala-gujarat-west-bengal-kolkata-deaths-recoveries-health-ministry-894534.html" target="_blank">For live updates on the coronavirus outbreak, click here</a></strong></p>.<p>Similar to a pregnancy strip test, Feluda changes colour if the virus is detected and doesn’t need expensive machines for detection.</p>.<p>“The CRISPR technology uses a highly specific CAS9 protein to find and bind to the target Covid signature. This is then coupled with paper-strip chemistry to elicit a visual readout on a paper strip,” Chakraborty explained.</p>.<p>The test can help the country, with the world’s second highest cases of Covid-19 at 61.45 lakh cases, ramp up testing of the disease quickly and economically, the researchers behind the test said in a statement.</p>.<p>Virologist Upasana Ray noted that the CRISPR based Covid-19 detection system is a cheaper option to RT-PCR tests, which cost over Rs 1,600. RAT and Feluda are in the same price bracket.</p>.<p>FELUDA, an acronym for the FNCAS9 Editor-Limited Uniform Detection Assay, uses an indigenously developed, cutting-edge CRISPR technology for detection of the genomic sequence of SARS-CoV-2 virus, the scientists said.</p>.<p>CRISPR is a gene editing technology and is used in correcting genetic defects and treating and preventing the spread of diseases.</p>.<p>The technology can detect specific sequences of DNA within a gene, and uses an enzyme functioning as molecular scissors to snip it.</p>.<p><strong>Also Read: <a href="https://www.deccanherald.com/opinion/covid-19-vaccine-not-for-me-thank-you-894674.html" target="_blank">Covid-19 vaccine? Not for me, thank you</a></strong></p>.<p>According to Ray, Feluda is capable of detecting even low quantities of the genetic material of the novel coronavirus, based on very minute differences in their RNA – the genetic material of a virus</p>.<p>“Feluda is an alternative to the quantitative RT-PCR tests and is highly specific. It is capable of detecting low copy number nucleic acids (less viral RNA quantity) as well as single nucleotide variations,” Ray, a senior scientist at CSIR-IICB, Kolkata, told PTI.</p>.<p>She explained that the tests are so specific that they can distinguish SARS-CoV-2 infections from other coronaviruses such as the one that caused the 2002-03 SARS pandemic.</p>.<p>“It can distinguish between SARS-CoV-2 and SARS-CoV sequences which differ by a single nucleotide. Unlike RT-PCR which requires expensive machines, Feluda is simple and can be used in laboratories as well as outside with a quicker turnaround time,” she added.</p>.<p>In May, the US granted emergency-use approval for the world’s first CRISPR-based test for Covid-19, developed by the Massachusetts Institute of Technology (MIT) and Harvard University.</p>.<p>The CRISPR Feluda test is the world’s first diagnostic test to deploy a specially adapted Cas9 protein, derived from Francisella novicida bacteria, to successfully detect the virus that causes Covid-19, the researchers said.</p>.<p>Other CRISPR tests, like the one developed in the US, use CAS12 and CAS13 proteins to detect SARS-CoV-2.</p>.<p>Compared with a rapid antigen test, which interprets results in 30 minutes, Ray said the Feluda test would take slightly longer, up to 45 minutes, but is more accurate and specific.</p>.<p>Rapid antigen tests detect the viral proteins or parts thereof whereas CRISPR detects nucleic acids, or RNA in case of Covid-19, Ray said.</p>.<p>Chakaraborty noted that RT-PCR takes about 1.5 hours, trained manpower and a dedicated and expensive RT-PCR machine which is not widely available.</p>.<p>"Feluda gives similar sensitivity and specificity as RT-PCR but is inexpensive, requires a basic widely available PCR machine and doesn’t require extensive trained manpower. The chemistry and biology is of course different,” Chakraborty added.</p>.<p>“This marks a significant achievement for the Indian scientific community, moving from R&D to a high-accuracy, scalable and reliable test in less than 100 days. The Tata CRISPR test achieves accuracy levels of traditional RT-PCR tests, with quicker turnaround time, less expensive equipment, and better ease of use,” the researchers said in their statement.</p>.<p>They described CRISPR as a futuristic technology that can also be configured for the detection of other pathogens.</p>.<p>“Current R&D is towards making Feluda more point of care, simpler and more deployable to meet the testing needs of the country and enable return to workplaces, schools, etc,” Chakraborty added. </p>
<p>More accurate than a rapid antigen test and almost as quick, India’s CRISPR ‘Feluda’ Covid-19 test that changes colour on detection of the SARS-CoV-2 virus could be a cheaper, faster and simpler alternative to an RT-PCR diagnosis, say scientists.</p>.<p>Named after Satyajit Ray’s famed detective, the Feluda test, which is priced at Rs 500 and can deliver a result in 45 minutes, is able to differentiate SARS-CoV-2 from other coronaviruses even if genetic variations between them are minute.</p>.<p>The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Feluda test, developed by the New Delhi-based CSIR-Institute of Genomics and Integrative Biology (IGIB) and the TATA Group, received regulatory approvals last week from the Drug Controller General of India (DCGI) for commercial launch.</p>.<p>It meets high quality benchmarks with 96 per cent sensitivity and 98 per cent specificity for detecting the novel coronavirus, Debojyoti Chakraborty, a senior scientist at CSIR-IGIB and part of the team that developed the test, told PTI.</p>.<p>Sensitivity is defined as the ability of a test to correctly identify individuals with the disease, while specificity is the ability of the assay to accurately identify those without the disease.</p>.<p><strong><a href="https://www.deccanherald.com/national/coronavirus-news-live-updates-india-world-coronavirus-vaccine-astrazeneca-Covid-19-karnataka-bengaluru-maharashtra-mumbai-tamil-nadu-chennai-delhi-kerala-gujarat-west-bengal-kolkata-deaths-recoveries-health-ministry-894534.html" target="_blank">For live updates on the coronavirus outbreak, click here</a></strong></p>.<p>Similar to a pregnancy strip test, Feluda changes colour if the virus is detected and doesn’t need expensive machines for detection.</p>.<p>“The CRISPR technology uses a highly specific CAS9 protein to find and bind to the target Covid signature. This is then coupled with paper-strip chemistry to elicit a visual readout on a paper strip,” Chakraborty explained.</p>.<p>The test can help the country, with the world’s second highest cases of Covid-19 at 61.45 lakh cases, ramp up testing of the disease quickly and economically, the researchers behind the test said in a statement.</p>.<p>Virologist Upasana Ray noted that the CRISPR based Covid-19 detection system is a cheaper option to RT-PCR tests, which cost over Rs 1,600. RAT and Feluda are in the same price bracket.</p>.<p>FELUDA, an acronym for the FNCAS9 Editor-Limited Uniform Detection Assay, uses an indigenously developed, cutting-edge CRISPR technology for detection of the genomic sequence of SARS-CoV-2 virus, the scientists said.</p>.<p>CRISPR is a gene editing technology and is used in correcting genetic defects and treating and preventing the spread of diseases.</p>.<p>The technology can detect specific sequences of DNA within a gene, and uses an enzyme functioning as molecular scissors to snip it.</p>.<p><strong>Also Read: <a href="https://www.deccanherald.com/opinion/covid-19-vaccine-not-for-me-thank-you-894674.html" target="_blank">Covid-19 vaccine? Not for me, thank you</a></strong></p>.<p>According to Ray, Feluda is capable of detecting even low quantities of the genetic material of the novel coronavirus, based on very minute differences in their RNA – the genetic material of a virus</p>.<p>“Feluda is an alternative to the quantitative RT-PCR tests and is highly specific. It is capable of detecting low copy number nucleic acids (less viral RNA quantity) as well as single nucleotide variations,” Ray, a senior scientist at CSIR-IICB, Kolkata, told PTI.</p>.<p>She explained that the tests are so specific that they can distinguish SARS-CoV-2 infections from other coronaviruses such as the one that caused the 2002-03 SARS pandemic.</p>.<p>“It can distinguish between SARS-CoV-2 and SARS-CoV sequences which differ by a single nucleotide. Unlike RT-PCR which requires expensive machines, Feluda is simple and can be used in laboratories as well as outside with a quicker turnaround time,” she added.</p>.<p>In May, the US granted emergency-use approval for the world’s first CRISPR-based test for Covid-19, developed by the Massachusetts Institute of Technology (MIT) and Harvard University.</p>.<p>The CRISPR Feluda test is the world’s first diagnostic test to deploy a specially adapted Cas9 protein, derived from Francisella novicida bacteria, to successfully detect the virus that causes Covid-19, the researchers said.</p>.<p>Other CRISPR tests, like the one developed in the US, use CAS12 and CAS13 proteins to detect SARS-CoV-2.</p>.<p>Compared with a rapid antigen test, which interprets results in 30 minutes, Ray said the Feluda test would take slightly longer, up to 45 minutes, but is more accurate and specific.</p>.<p>Rapid antigen tests detect the viral proteins or parts thereof whereas CRISPR detects nucleic acids, or RNA in case of Covid-19, Ray said.</p>.<p>Chakaraborty noted that RT-PCR takes about 1.5 hours, trained manpower and a dedicated and expensive RT-PCR machine which is not widely available.</p>.<p>"Feluda gives similar sensitivity and specificity as RT-PCR but is inexpensive, requires a basic widely available PCR machine and doesn’t require extensive trained manpower. The chemistry and biology is of course different,” Chakraborty added.</p>.<p>“This marks a significant achievement for the Indian scientific community, moving from R&D to a high-accuracy, scalable and reliable test in less than 100 days. The Tata CRISPR test achieves accuracy levels of traditional RT-PCR tests, with quicker turnaround time, less expensive equipment, and better ease of use,” the researchers said in their statement.</p>.<p>They described CRISPR as a futuristic technology that can also be configured for the detection of other pathogens.</p>.<p>“Current R&D is towards making Feluda more point of care, simpler and more deployable to meet the testing needs of the country and enable return to workplaces, schools, etc,” Chakraborty added. </p>